Literature DB >> 10773929

Efficacy of leucocyte filters during transfusions in preventing the development of anti-HLA antibodies.

S Kurul1, H Ozkan, O Anal, N Akkoç, G Irken.   

Abstract

The study was planned to investigate the effectiveness of using leucocyte filters in neonates during exchange and erythrocyte transfusion in preventing the development of anti-HLA antibodies. Twenty-four newborn infants who were admitted to the Neonatology Unit and received either exchange or at least two erythrocyte transfusions were recruited. The study group comprised of 12 infants on whom leucocyte filters were used during transfusions. Control group included the remaining 12 infants who were transfused without using a leucocyte filter. Anti-HLA antibodies in the serum samples were studied using modified Amos technique. Presence of anti-HLA antibodies in post-transfusion sera was detected in 3 (25%) of 12 infants in the study (filter) group, while in 10 (83.33%) of 12 infants in the control (no-filter) group. The difference between two groups was statistically significant (p < 0.05). The study demonstrated that term and preterm neonates were capable of developing anti-HLA antibodies following exchange and erythrocyte transfusions, and use of leucocyte filters could efficiently prevent the formation of anti-HLA antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10773929     DOI: 10.1007/bf02731054

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  12 in total

1.  Intramolecular specificity of anti-HLA alloantibodies.

Authors:  N Akkoc; J C Scornik
Journal:  Hum Immunol       Date:  1991-02       Impact factor: 2.850

2.  Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions.

Authors:  D B Brubaker
Journal:  Transfusion       Date:  1990-10       Impact factor: 3.157

3.  Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.

Authors:  L M Williamson; J Z Wimperis; P Williamson; J A Copplestone; H C Gooi; G R Morgenstern; D R Norfolk
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

4.  Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia. Finnish Leukemia Group.

Authors:  K Oksanen; E Elonen
Journal:  Br J Haematol       Date:  1993-08       Impact factor: 6.998

5.  Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.

Authors:  U M Saarinen; R Kekomäki; M A Siimes; G Myllylä
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

6.  Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.

Authors:  G Andreu; J Dewailly; C Leberre; M C Quarre; M L Bidet; R Tardivel; L Devers; Y Lam; E Soreau; C Boccaccio
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

7.  Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer.

Authors:  U M Saarinen; S Koskimies; G Myllylä
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

8.  Post-transfusion purpura as the main manifestation of a trilineal transfusion reaction, responsive to steroids: flow-cytometric investigation of granulocyte and platelet antibodies.

Authors:  N Puig; M J Sayas; J A Montoro; J V Villalba; A Pla
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

9.  Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters.

Authors:  M A Ten Haaft; P M Van den Berg-Loonen; D J Van Rhenen
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

Review 10.  The normal fetomaternal immune relationship.

Authors:  W D Billington
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1992-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.